Wednesday 2nd April, 2014
8:30am to 4:40pm
The global market for Asthma and COPD drugs is set to reach $47bn in 2017. There is a growing demand for the next generation of inhaled combination products and novel therapeutics.
Asthma and COPD 2014 will enable delegates to gain valuable insights into the latest ground-breaking advances in the respiratory drug market. It will focus on the challenges and strategies to enhance patient outcomes, providing extensive knowledge from the key leading industry and academic experts.
Business Benefits for 2014:
The 10th annual event is now well known and established within the industry.
Comments from previous instalments include: "Excellent, both days" – Prosonix, "Good Networking opportunities" – Novartis
Category: Conferences/Trade show
Conference and workshop: £2098+vat
Conference Only: £1499+vat
Principal Scientist, Translational Medicine-RIA, MedImmune
Senior Medical Assessor, MHRA
Professor of Respiratory Medicine and Head of Experimental Studies Medicine, National Heart and Lung Institute
Director of Research, British Lung Foundation
Director/Unit Head for Pre-Clinical Biomarkers Respiratory Disease Area, Novartis
Sign in to add slides, notes or videos to this session